5 Amendments of Dolors MONTSERRAT related to 2019/2816(RSP)
Amendment 117 #
Paragraph 10
10. Asks for a special focus to be putUnderlines the need to gather new and more detailed data on emission hot spots, such as hospitals and pharmaceutical production plants, and the use of digital and big data monitoring systems;
Amendment 183 #
Paragraph 21 a (new)
21 a. Calls on the European Medicines Agency to facilitate joint inspections of manufacturing discharges at overseas pharmaceuticals factories supplying the EU;
Amendment 195 #
Paragraph 25 a (new)
25 a. Calls on the Commission to support research on the assessment of mixture effects, chronic exposition on low dose and antimicrobial resistance development, especially in relation to vulnerable groups of population;
Amendment 197 #
Paragraph 26
26. Stresses that measures must be based on scientific evidence and calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to safely extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;
Amendment 200 #
Paragraph 27
27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ healthcausing difficulties in the access to medicines and not reducing the effectiveness of treatments; is of the opinion that the overall per animal veterinary medicines consumption should also decrease and better alternatives should be found;